Spatially fractionated radiotherapy with PD-L1 blockade achieves superior antitumor efficacy and safety in a preclinical model of peritoneal metastasis
- 1Department of Radiation Oncology, Samsung Medical Center, Seoul, 06351 Republic of Korea
- 2Department of Radiation Oncology, Sungkyunkwan University School of Medicine, Seoul, 06351 Republic of Korea
Abstract
Peritoneal metastasis from gastrointestinal cancers has poor outcomes, and whole-abdominal radiotherapy (RT) is limited by toxicity to radiosensitive organs. Spatially fractionated radiotherapy (SFRT) delivers heterogeneous doses, potentially sparing normal tissue while stimulating antitumor immunity. This study aimed to evaluate the efficacy, safety, and immune modulation of SFRT combined with PD-L1 blockade in a syngeneic peritoneal metastasis model. Mouse-specific grid collimators (2–4 mm) were fabricated and tested. CT26-luc cells were injected intraperitoneally, followed by conventional RT (CONV) or 3 mm SFRT at 8–16 Gy, with or without anti–PD-L1. Tumor burden was assessed by bioluminescence, survival and weight monitored, and necropsy performed to evaluate toxicity. Immune profiling of ascites and blood was performed by flow cytometry, and functional outcomes by open-field testing. The 3 mm grid achieved a peak-to-valley dose ratio of ~ 11 and was used for therapy. At 8 Gy, SFRT provided tumor control comparable to CONV RT with less weight loss. At 10 Gy, CONV RT caused early mortality, whereas SFRT maintained 100% survival. SFRT plus anti–PD-L1 induced near-complete tumor regression, reduced ascites, and preserved intestinal length. Immune analysis showed increased CD4⁺/CD8⁺ T cells and M1 macrophages with SFRT; combination therapy further expanded T cells and yielded the lowest neutrophil-to-lymphocyte ratio. Functional testing demonstrated improved locomotion with SFRT plus anti–PD-L1. SFRT combined with PD-L1 blockade achieves potent tumor control, reduces toxicity, and enhances physical performance, supporting its potential as a safer immuno-radiotherapy strategy for peritoneal metastasis.
Supplementary Information: The online version contains supplementary material available at https://doi.org/10.1007/s00262-026-04505-w.
Related
- Clinical Outcomes and Safety of Spatially Fractionated Radiotherapy for Malignant Tumors: A Systematic Review and Evidence Map
- Spatially fractionated (GRID) radiotherapy in a patient with metastatic pleomorphic rhabdomyosarcoma: a case report
- Clinical outcomes and toxicity after proton- versus photon-based spatially fractionated radiotherapy for soft-tissue sarcoma: a retrospective cohort
- Pilot study on microwave preclinical system for targeted delivery of fractionated hyperthermia in murine solid tumors
- Whole peritoneal radiotherapy in malignant ascites: a hypothesis-generating conceptual review
BibTeX
@article{lee2026spatially,
title = {{Spatially fractionated radiotherapy with PD-L1 blockade achieves superior antitumor efficacy and safety in a preclinical model of peritoneal metastasis}},
author = {Sung Eun Lee and Changhoon Choi and Yeeun Kim and Taehyung Kim and Sung Jin Kim and Sang Hoon Jung and Jeong Il Yu},
journal = {Cancer Immunology, Immunotherapy : CII},
year = {2026},
month = aug,
doi = {10.1007/s00262-026-04505-w},
url = {https://doi.org/10.1007/s00262-026-04505-w},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Spatially fractionated radiotherapy with PD-L1 blockade achieves superior antitumor efficacy and safety in a preclinical model of peritoneal metastasis
AU - Sung Eun Lee
AU - Changhoon Choi
AU - Yeeun Kim
AU - Taehyung Kim
AU - Sung Jin Kim
AU - Sang Hoon Jung
AU - Jeong Il Yu
PY - 2026
DA - 2026/08/06
JO - Cancer Immunology, Immunotherapy : CII
DO - 10.1007/s00262-026-04505-w
UR - https://doi.org/10.1007/s00262-026-04505-w
AB - Peritoneal metastasis from gastrointestinal cancers has poor outcomes, and whole-abdominal radiotherapy (RT) is limited by toxicity to radiosensitive organs. Spatially fractionated radiotherapy (SFRT) delivers heterogeneous doses, potentially sparing normal tissue while stimulating antitumor immunity. This study aimed to evaluate the efficacy, safety, and immune modulation of SFRT combined with PD-L1 blockade in a syngeneic peritoneal metastasis model. Mouse-specific grid collimators (2–4 mm) were fabricated and tested. CT26-luc cells were injected intraperitoneally, followed by conventional RT (CONV) or 3 mm SFRT at 8–16 Gy, with or without anti–PD-L1. Tumor burden was assessed by bioluminescence, survival and weight monitored, and necropsy performed to evaluate toxicity. Immune profiling of ascites and blood was performed by flow cytometry, and functional outcomes by open-field testing. The 3 mm grid achieved a peak-to-valley dose ratio of ~ 11 and was used for therapy. At 8 Gy, SFRT provided tumor control comparable to CONV RT with less weight loss. At 10 Gy, CONV RT caused early mortality, whereas SFRT maintained 100% survival. SFRT plus anti–PD-L1 induced near-complete tumor regression, reduced ascites, and preserved intestinal length. Immune analysis showed increased CD4⁺/CD8⁺ T cells and M1 macrophages with SFRT; combination therapy further expanded T cells and yielded the lowest neutrophil-to-lymphocyte ratio. Functional testing demonstrated improved locomotion with SFRT plus anti–PD-L1. SFRT combined with PD-L1 blockade achieves potent tumor control, reduces toxicity, and enhances physical performance, supporting its potential as a safer immuno-radiotherapy strategy for peritoneal metastasis. Supplementary Information: The online version contains supplementary material available at https://doi.org/10.1007/s00262-026-04505-w.
SN - 0340-7004
SN - 1432-0851
ER -